Join
Live feed
·
INSIDERFilingvia Quantisnow
Kalaris Therapeutics Inc. logo

Director Akkaraju Srinivas was granted 1,500,000 shares (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
KLRS· Kalaris Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KLRS (Kalaris Therapeutics Inc.) and more on Quantisnow.